Items Tagged ‘early-stage’

September 7th, 2016

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo

By

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results need to be validated, and compared to other tests in order to confirm findings and determine true clinical utility […]

View full entry

Tags: Breast Cancer, early-stage, hereditary, MammaPrint, News, Stage I Node Negative Breast Cancer


July 11th, 2016

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

By

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Chronic lymphocytic leukemia is the most common form of adult leukemia. The American […]

View full entry

Tags: 2016, asco, Bruton’s tyrosine kinase, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CLL, early-stage, ibrutinib, imbruvica, Leukemia, News


June 7th, 2016

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer

By

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of […]

View full entry

Tags: AIs, aromatase inhibitors, Breast Cancer, early-stage, hormone-positive, HR+, News, postmenopausal, Stage I Node Negative Breast Cancer, survival


July 15th, 2015

More Men with Low-Risk Prostate Cancer Are Delaying Treatment until Progression

By

Increasingly more men with low-risk, early-stage prostate cancer appear to choose active surveillance (or watchful waiting) instead of treatment. As a result, they’re avoiding the risk of long-term side effects of treatment. These findings were reported in the Journal of the American Medical Association. The treatment of early-stage prostate cancer with low risk of progression […]

View full entry

Tags: active surveillance, Early Stage I-II (A-B) Prostate Cancer, early-stage, low-risk, News, Prostate Cancer, side effects, treatment, watchful waiting


June 2nd, 2015

Combination of Iniparib, Gemzar®, and Carboplatin Active in Initial Treatment of Early-Stage Triple-Negative Breast Cancer

By

The combination of iniparib, Gemzar® (gemcitabine), and carboplatin appears promising in the initial treatment of patients with early-stage triple-negative breast cancer with a BRCA1/2 mutation. In addition, researchers have found ways to identify patients without a BRCA mutation who are likely to benefit. These findings were published in the Journal of Clinical Oncology. Breast cancers […]

View full entry

Tags: BRCA1/2 mutation, Breast Cancer, carboplatin, early-stage, gemzar, Iniparib, News, Stage I Node Negative Breast Cancer, Triple Negative Breast Cancer


April 30th, 2015

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer

By

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved disease-free survival. These findings were released online by the journal The Lancet. Node-positive breast cancer means that cancer cells from the breast have been found in the lymph nodes under the arm. Although […]

View full entry

Tags: Breast Cancer, cyclophosphamide, Cytoxan, early-stage, Ellence, epirubicin, fluorouracil, News, node-positive, paclitaxel, Stages II-III Breast Cancer, Taxol